tradingkey.logo


tradingkey.logo


Impact Biomedical Inc

IBO

詳现チャヌトを衚瀺
0.472USD
+0.014+2.92%
終倀 02/06, 16:00ET15分遅れの株䟡
5.75M時䟡総額
損倱額盎近12ヶ月PER


Impact Biomedical Inc

0.472
+0.014+2.92%
Intraday
1m
30m
1h
D
W
M
D

本日

+2.92%

5日間

-3.73%

1ヶ月

-6.04%

6ヶ月

-22.92%

幎初来

-6.59%

1幎間

-79.31%

詳现チャヌトを衚瀺

TradingKey 株匏スコア

デヌタが䞍十分なため、株匏スコアは利甚できたせん。

Impact Biomedical Inc ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

䌚瀟から関連デヌタがただ開瀺されおいたせん。

総売䞊高

䌚瀟から関連デヌタがただ開瀺されおいたせん。

Impact Biomedical Incの䌁業情報

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
䌁業コヌドIBO
䌁業名Impact Biomedical Inc
最高経営責任者「CEO」Heuszel (Frank D)
りェブサむトhttps://www.impactbiomedinc.com/
KeyAI
î™